08622.HK
Huakang Biomedical Holdings Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 0.23
−4.17%Year over year
Reported trailing growth
- Revenue
- +26.2%
- EBITDA
- -7.7%
- EBIT
- -57.7%
- EPS
- -25.6%
- Free cash flow
- -94.2%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +3.7%
- EBITDA
- —
- EBIT
- -37.3%
- Net income
- -20.4%
- EPS
- -16.3%
- Free cash flow
- +34.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026